Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
141.6 USD | -0.45% | +4.04% | +7.51% |
Financials (USD)
Sales 2024 * | 2.22B | Sales 2025 * | 2.54B | Capitalization | 14.26B |
---|---|---|---|---|---|
Net income 2024 * | 430M | Net income 2025 * | 661M | EV / Sales 2024 * | 5.52 x |
Net cash position 2024 * | 2B | Net cash position 2025 * | 2.79B | EV / Sales 2025 * | 4.51 x |
P/E ratio 2024 * |
34.6
x | P/E ratio 2025 * |
22.5
x | Employees | 1,448 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.2% |
Latest transcript on Neurocrine Biosciences, Inc.
1 day | -0.45% | ||
1 week | +4.04% | ||
Current month | +2.99% | ||
1 month | +7.31% | ||
3 months | +6.78% | ||
6 months | +29.44% | ||
Current year | +7.51% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.65% | 254 M€ | +10.44% | - | |
3.81% | 1 M€ | +0.15% | - | |
1.85% | 8 M€ | +5.66% | ||
1.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 141.6 | -0.45% | 500,626 |
24-05-17 | 142.3 | +0.27% | 641,937 |
24-05-16 | 141.9 | -0.06% | 670,978 |
24-05-15 | 142 | +2.54% | 684,685 |
24-05-14 | 138.5 | +1.71% | 637,476 |
Delayed Quote Nasdaq, May 20, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.51% | 14.26B | |
+9.58% | 115B | |
+12.41% | 107B | |
-3.55% | 21.6B | |
-12.38% | 22.31B | |
-6.54% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+35.67% | 12.37B | |
-24.50% | 8.28B |
- Stock Market
- Equities
- NBIX Stock